Reading infections, one plasma sample at a time
What Karius actually does, in plain English.
Karius runs a single test. You ship them a vial of blood. Their lab fishes out the microbial cell-free DNA - the genetic confetti shed by bacteria, viruses, fungi and parasites circulating in plasma - sequences it, and matches the fragments against a reference database of more than a thousand organisms. Days that used to be spent culturing and biopsying collapse into one report.
The patients who need this most are the ones least able to wait: bone-marrow transplant recipients, leukemia patients in febrile neutropenia, anyone whose immune system has been disarmed long enough for an opportunistic pathogen to settle in somewhere a swab can't reach. Ford's pitch to hospital systems is built around them.
"Often overshadowed by their primary diagnosis but equally lethal - leading to nearly 1,000 deaths daily." - Alec Ford, May 2024
October 2020. A pandemic. A handoff.
Ford was announced as CEO on October 6, 2020, eight months into a global pandemic in which the words "rapid pathogen identification" had stopped being technical jargon and become dinner-table conversation. He took the chair from Mickey Kertesz, the company's co-founder, who slid sideways into President and Chief Product Officer rather than out the door - an unusually graceful handoff in a sector that often resembles a Greek tragedy with quarterly reporting.
"The opportunity to lead such a dedicated and talented team of scientists and other professionals at Karius," Ford said at the time, "is a unique opportunity to accelerate the founders' vision." He sounded, even then, like the operator he was hired to be.
If you can find the cause of infection quickly, you can narrow someone's therapy. We try to do everything we can to help a patient get on the right antibiotics sooner.- Alec Ford, on Karius's clinical promise
Pfizer, Sanofi, Nektar, Novartis, Myriad - then Karius
Before he was a CEO, Ford was the COO at Myriad Genetics, the molecular-diagnostics company best known for its hereditary cancer panels. He launched products and scaled new business units across Women's Health, Oncology, Urology and Prenatal screening - which, translated, means he spent years navigating the four messiest reimbursement landscapes in American medicine without breaking the company.
Before Myriad, he held leadership roles at Novartis, Sanofi-Aventis, Nektar Therapeutics and Pfizer. The pattern is consistent: big pharma, then specialty pharma, then diagnostics, then a diagnostics company built around sequencing. Each move trades scale for proximity to the patient.
His degree, from NYU, is in Organizational Development. It is not the credential you'd expect on a biotech CEO's wall. It is, possibly, the most useful one. Karius is not a science problem any more - the science works. It is an organizational problem: get a complex molecular test paid for, run at scale, and trusted in 2 a.m. ICU decisions.
A sister, an epidemiologist, a reason
In an interview with Authority Magazine, Ford talked about losing his sister - an epidemiologist at the University of Texas - to inflammatory breast cancer. The line he keeps returning to in interviews is that cancer touches everyone, and that infection is the part of the cancer story most often missed in obituaries. About half the deaths attributed to cancer are, on closer inspection, deaths from infections that the cancer or its treatment opened the door to.
He calls himself a "facilitator of change." It's a quieter self-description than the genre usually allows. He follows it with a sharper line: "If that change doesn't happen, it's all just talk."
Cancer touches everyone - and it changed how I think about preventable cancer.- Alec Ford, on the loss that reshaped his career
$100 million, three new investors, one antibiotic-resistance crisis
On May 2, 2024, Karius announced a $100 million Series C, co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare, with Seventure Partners joining the cap table. Existing backers - SoftBank Vision Fund 2, General Catalyst, HBM, Blue Water Life Sciences, Innovation Endeavors, Waycross Ventures - rolled their support forward. The round brought total funding to roughly $345 million.
The framing wasn't just growth. It was the antimicrobial-resistance crisis: the more confidently a clinician can identify the actual pathogen behind a fever, the more confidently they can stop pouring broad-spectrum antibiotics into a patient who didn't need them. Karius is, in that argument, both a diagnostic and a stewardship tool.
Three new directors joined the board with the round: Alex Morgan (Khosla), Joep Muijrers (Gilde) and Andrew Booth (5AM). Ford got the headline, the capital, and three new bosses, in that order.
By the digits
Operator, not evangelist
Founders sell vision; Ford sells throughput. Listen to him in interviews and the language is patient, almost flat: timing, therapy, the right antibiotic, sooner. He doesn't reach for the messianic register the diagnostics industry sometimes loves. He reaches for the bedside.
He grew up in Chicago, one of three kids. He helped found BioUtah, the state's life-sciences trade group, during his Myriad years - the kind of unglamorous association work that doesn't show up in TechCrunch but does show up later when you need policymakers to understand why a sequencing-based test should be a covered benefit.
If that change doesn't happen, it's all just talk.- Alec Ford, on the gap between mission statements and behavior